Breaking News Instant updates and real-time market news.

TSRO

TESARO

$148.85

5.27 (3.67%)

, ARIA

ARIAD

$23.75

10.01 (72.85%)

08:11
01/10/17
01/10
08:11
01/10/17
08:11

ARIAD acquisition supports potential takeout premium for TESARO, says Leerink

Leerink analyst Seamus Fernandez says the acquisition of ARIAD (ARIA) by Takeda (TKPYY) for $24 per share appears to be relatively in-line with other commercial stage acquisitions, and supports a potential acquisition price for TESARO (TSRO) of greater than $170 per share based on consensus forecasts. While TESARO remains well positioned to grow independently, the analyst believes a validated PARP inhibitor like niraparib could offer a durable and strategically important product opportunity for multiple suitors. He reiterates an Outperform rating on TESARO's shares.

TSRO

TESARO

$148.85

5.27 (3.67%)

ARIA

ARIAD

$23.75

10.01 (72.85%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$21.72

0.33 (1.54%)

  • 11

    Jan

  • 11

    Jan

  • 11

    Jan

  • 21

    Feb

  • 29

    Apr

  • 30

    Jun

TSRO TESARO
$148.85

5.27 (3.67%)

12/21/16
JANY
12/21/16
NO CHANGE
Target $44
JANY
Neutral
Clovis price target raised to $44 from $38 at Janney Capital
Janney Capital analyst Debjit Chattopadhyay raised his price target for Clovis Oncology to $44 to reflect his assumption of $36M in Rubraca sales for FY17. Clovis is launching Rubraca in the U.S. with around 85 sales reps, and the analyst assumes a similar sized organization in the major European markets. He assumes Clovis launches the drug without a partner in Europe. He believes the FDA's position on competitor TESARO's (TSRO) niraparib will have implications for Clovis prior to the ARIEL3 data. Chattopadhyay keeps a Neutral rating on Clovis. The stock is up 8% to $45.86 in midday trading.
01/09/17
LEER
01/09/17
NO CHANGE
Target $152
LEER
Outperform
TESARO price target raised to $152 from $115 at Leerink
Leerink analyst Seamus Fernandez raised his price target for TESARO to $152 from $115 to fully incorporate his high expectations for a broad label and reflect niraparib's transformation to a commercial stage asset. The analyst notes that the "strong data" from niraparib's NOVA trial, along with the lack of an expected FDA panel, should result in a broad label in the second-line or greater ovarian cancer maintenance setting, while ongoing niraparib trials in breast cancer and front-line ovarian cancer maintenance and the company's IO platform should be additional potential drivers of upside for the stock. Fernandez sees TESARO as an "attractive takeout target," and reiterates an Outperform rating on the shares.
01/04/17
GABE
01/04/17
NO CHANGE
GABE
Gabelli sees Incyte as more likely target following Gilead hire
Gilead (GILD) is more likely to buy Incyte (INCY) after naming Alessandro Riva to head its Hematology and Oncology Therapeutic unit, Gabelli analyst Jing He tells investors in a research note. Dr. Riva is a Novartis (NVS) veteran while Incyte is led by a team of Novartis veterans and has collaborated with Novartis Oncology on its key drug, Jakafi, the analyst points out. He believes Incyte is "big enough to move the needle" and bring long term growth to Gilead. The analyst lists Seattle Genetics (SGEN) and TESARO (TSRO) as other potential targets for the biotech giant. He believes Incyte is the "best fit."
12/27/16
FBRC
12/27/16
NO CHANGE
Target $151
FBRC
Outperform
FBR Capital ups TESARO price target to $151
FBR Capital analyst Ed White raised his price target for TESARO to $151 from $133 and keeps the Outperform rating on the shares. The oncology-focused biopharmaceutical company closed Friday up $7.27 to $139.86. TESARO recently announced that the FDA has granted Priority Review for niraparib with a June 30, 2017 action date, White tells investors in a research note. He believes niraparib could be a potential blockbuster PARP inhibitor. Meanwhile, the launch of Varubi continues to "ramp up," with sequential quarter-over-quarter unit growth of 14%, the analyst writes. White says the drug achieved a 28% share of the oral NK-1 market in the U.S. in September.
ARIA ARIAD
$23.75

10.01 (72.85%)

12/01/16
WBLR
12/01/16
NO CHANGE
WBLR
Celgene, Zoetis among top healthcare picks at William Blair
William Blair analysts named their top health care picks for 2017, identifying Evolent Health (EVH) as their top HC Services and HC IT pick, Zoetis (ZTS) as their top dental and animal health pick,and Pacific Biosciences (PACB) as their top diagnostic services and life sciences choice, The firm identified ARIAD (ARIA), Celgene (CELG) and SAGE Therapeutics (SAGE) as their top biotech choices. It named Edwards Lifesciences (EW), Nevro (NVRO), and K2M Group (KTWO) as its favorite med tech picks.
11/03/16
11/03/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BioMarin (BMRN) initiated with a Buy at Deutsche Bank. 2. Ambev (ABEV) reinstated with an Equal Weight at Barclays. 3. ARIAD (ARIA) initiated with a Hold at Deutsche Bank. 4. Thomson Reuters (TRI) reinstated with a Neutral at JPMorgan. 5. Exelixis (EXEL) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage click here.
01/10/17
LEHM
01/10/17
UPGRADE
Target $24
LEHM
Equal Weight
ARIAD upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Paul Choi upgraded ARIAD Pharmaceuticals to Equal Weight saying the all cash acquisition by Takeda is a positive outcome for shareholders. The analyst assumes the deal closes with no competing bids and upped his price target for the shares to $24 from $9.
01/10/17
JEFF
01/10/17
DOWNGRADE
Target $24
JEFF
Hold
ARIAD downgraded to Hold from Buy at Jefferies
Jefferies analyst Eun Yang downgraded ARIAD Pharmaceuticals to Hold on expectations the Takeda acquisition will close by the end of February. The analyst views the deal as a "nice surprise at a significant premium." She raised her price target for the shares to $24 from $11.
TKPYY Takeda Pharmaceutical Co. Ltd.
$21.72

0.33 (1.54%)

06/08/16
RHCO
06/08/16
NO CHANGE
RHCO
Ultragenyx collaboration with Takeda 'exceptionally positive,' says SunTrust
After Ultragenyx (RARE) announced a development and commercialization collaboration for rare genetic diseases with Takeda (TKPYY), SunTrust says the deal terms are "exceptionally positive" for Ultragenyx. The firm notes that the latter company will receive both compounds and cash payments from Takeda, while Takeda will only get comemrcial rights in Asia. The firm keeps a Buy rating on Ultragenyx.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.
09/14/16
SBSH
09/14/16
NO CHANGE
Target $4
SBSH
Neutral
Citi views Synergy Pharmaceuticals as potential target for Takeda
Citi analyst Liav Abraham calls Synergy Pharmaceuticals (SGYP) the most likely potential target for Takeda Pharmaceutical (TKPYY) among her coverage universe. The Financial Times earlier today reported that Takeda is ready to spend as much as $15B in acquisitions to expand its business in the United States. Abraham has a Neutral rating on Synergy with a $4 price target. The analyst sees Synergy as a potential target given the "extensive resources" needed to commercialize its lead asset, plecanatide, as well as Takdea's presence in the irritable bowel syndrome/chronic idiopathic constipation space. Shares of Synergy are up 6% to $5.18 in early trading.
07/07/16
UBSW
07/07/16
INITIATION
UBSW
Neutral
Takeda Pharmaceutical initiated with a Neutral at UBS
UBS analyst Atsushi Seki started Takeda with a Neutral rating and Y4,600 price target.

TODAY'S FREE FLY STORIES

INTC

Intel

$35.75

0.18 (0.51%)

16:23
03/30/17
03/30
16:23
03/30/17
16:23
Initiation
Intel initiated  »

Intel initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

  • 05

    Apr

  • 27

    Apr

  • 02

    May

DRIO

DarioHealth

$3.90

-0.0899 (-2.25%)

16:21
03/30/17
03/30
16:21
03/30/17
16:21
Syndicate
DarioHealth announces offering of common stock, no amount given »

Aegis Capital Corp. is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$11.61

0.19 (1.66%)

16:21
03/30/17
03/30
16:21
03/30/17
16:21
Options
Closing CBOE SPX and VIX Index summary for March 30th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$28.97

0.47 (1.65%)

16:21
03/30/17
03/30
16:21
03/30/17
16:21
Initiation
Micron initiated  »

Micron initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Apr

MULE

MuleSoft

$23.71

-0.09 (-0.38%)

16:20
03/30/17
03/30
16:20
03/30/17
16:20
Hot Stocks
Breaking Hot Stocks news story on MuleSoft »

Bain Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UCP

UCP, Inc.

$10.20

0.15 (1.49%)

, PICO

PICO Holdings

$13.90

-0.2 (-1.42%)

16:20
03/30/17
03/30
16:20
03/30/17
16:20
Hot Stocks
UCP, PICO Holdings announce several governance agreements »

UCP (UCP) together with…

UCP

UCP, Inc.

$10.20

0.15 (1.49%)

PICO

PICO Holdings

$13.90

-0.2 (-1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

AEHR

Aehr Test Systems

$5.41

0.18 (3.44%)

16:18
03/30/17
03/30
16:18
03/30/17
16:18
Hot Stocks
Aehr Test Systems CEO says Q3 revenue lower than expected on timing »

Gayn Erickson, President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

HIIQ

Health Insurance Innovations

$15.95

0.9 (5.98%)

16:18
03/30/17
03/30
16:18
03/30/17
16:18
Initiation
Health Insurance Innovations initiated  »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$26.59

-0.04 (-0.15%)

, LGF.B

Lionsgate

$24.53

-0.1 (-0.41%)

16:18
03/30/17
03/30
16:18
03/30/17
16:18
Initiation
Lionsgate, Lionsgate initiated  »

Lionsgate initiated with…

LGF.A

Lionsgate

$26.59

-0.04 (-0.15%)

LGF.B

Lionsgate

$24.53

-0.1 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

VJET

voxeljet

$2.85

0.03 (1.06%)

16:18
03/30/17
03/30
16:18
03/30/17
16:18
Earnings
voxeljet backs FY17 revenue view EUR26M-EUR28M »

Backs FY17 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VJET

voxeljet

$2.85

0.03 (1.06%)

16:17
03/30/17
03/30
16:17
03/30/17
16:17
Earnings
Breaking Earnings news story on voxeljet »

voxeljet sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSS

TSYS

$53.26

0.25 (0.47%)

16:17
03/30/17
03/30
16:17
03/30/17
16:17
Initiation
TSYS initiated  »

TSYS initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

GOOG

Alphabet

$831.50

0.09 (0.01%)

16:17
03/30/17
03/30
16:17
03/30/17
16:17
Initiation
Alphabet initiated  »

Alphabet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 22

    May

$NSD

NASDAQ Market Internals

16:17
03/30/17
03/30
16:17
03/30/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFX

Newfield Exploration

$36.71

0.41 (1.13%)

16:16
03/30/17
03/30
16:16
03/30/17
16:16
Hot Stocks
Newfield Exploration to build new water recycling facility in Oklahoma »

Newfield Exploration has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

FIS

FIS

$80.06

0.03 (0.04%)

16:16
03/30/17
03/30
16:16
03/30/17
16:16
Initiation
FIS initiated  »

FIS initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VJET

voxeljet

$2.85

0.03 (1.06%)

16:16
03/30/17
03/30
16:16
03/30/17
16:16
Earnings
voxeljet reports Q4 EPS (EUR0.80) vs (EUR0.65) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AEHR

Aehr Test Systems

$5.41

0.18 (3.44%)

16:16
03/30/17
03/30
16:16
03/30/17
16:16
Earnings
Aehr Test Systems reports Q3 (14c) vs. (21c) in Q316 »

Reports Q3 net sales were…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Mar

HQY

HealthEquity

$40.84

0.81 (2.02%)

16:16
03/30/17
03/30
16:16
03/30/17
16:16
Initiation
HealthEquity initiated  »

HealthEquity initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
03/30/17
03/30
16:16
03/30/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
03/30/17
03/30
16:15
03/30/17
16:15
General news
Breaking General news story  »

Week of 3/29 Fed Balance…

16:15
03/30/17
03/30
16:15
03/30/17
16:15
General news
Breaking General news story  »

New York Federal Reserve…

16:15
03/30/17
03/30
16:15
03/30/17
16:15
General news
Breaking General news story  »

Week of 3/20 Money Supply…

AVDL

Avadel Pharmaceuticals

$9.55

-0.18 (-1.85%)

16:14
03/30/17
03/30
16:14
03/30/17
16:14
Hot Stocks
Avadel to reduce French workforce by about 50 people »

Avadel Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ORIG

Ocean Rig UDW

$0.30

0.0733 (32.21%)

16:13
03/30/17
03/30
16:13
03/30/17
16:13
Hot Stocks
Ocean Rig UDW announces receipt of Nasdaq delisting notice »

Ocean Rig announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.